Europe

ABPI to introduce new clinical trial transparency measures

Friday, March 1, 2013 02:42 PM

The Association of the British Pharmaceutical Industry (ABPI) will put in place measures to monitor compliance to the clinical trial transparency provisions contained in the ABPI Code of Practice. An independent, third-party service provider will be appointed to undertake this work, and the ABPI will take on the responsibility for reporting non-compliance with trial registration and posting of summary results.

More... »

EMA: Small, medium enterprises see consistent improvement in drug approvals

Friday, March 1, 2013 02:39 PM

Micro, small and medium-sized enterprises (SMEs) registered with the SME office of the European Medicines Agency have seen a consistent improvement in the success rate of their marketing-authorization applications (MAAs) over the past seven years, according to the SME offices’s 2012 annual report.

More... »

Creabilis names Moukheibir to board of directors

Thursday, February 28, 2013 02:33 PM

Creabilis, a late clinical stage European biotechnology company specializing in developing treatments in dermatology, inflammation and pain, has appointed Catherine Moukheibir to its board of directors.

More... »

Sapiens attracts $9.8M for next generation deep brain stimulation therapy

Wednesday, February 27, 2013 10:01 AM

Sapiens Steering Brain Stimulation, an emerging medical technology company developing brain stimulation products, has raised $9.8 million from the Dutch investment group INKEF Capital, in a further extension of their Series A financing round. The proceeds will be used for the development of its Steering Brain Stimulation implant and procedure solutions to treat Parkinson's disease (PD) and other functional brain disorders.

More... »

Novartis, Dr. Vasella cancel non-compete agreement

Wednesday, February 20, 2013 09:29 AM

The Novartis board of directors and Dr. Daniel Vasella, chairman of the company’s board, have agreed to cancel Vasella’s non-compete agreement with Novartis and all related conditional compensation. The agreement was to take effect after Vasella steps down as chairman of the board on February 22, 2013.

More... »

Cromsource further expands Polish operations

Friday, February 15, 2013 11:17 AM

Cromsource, an international full service CRO, has opened of a new office building in Warsaw, Poland, and has completed moving key company services to the new location.

More... »

New IMI projects to revitalize antibiotic development

Wednesday, February 13, 2013 02:04 PM

The Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in health care, has launched the first two projects under its antimicrobial resistance research program, New Drugs for Bad Bugs (ND4BB). The new projects, COMBACTE (Combating Bacterial Resistance in Europe) and TRANSLOCATION (Molecular basis of the bacterial cell wall permeability), are set to revitalize antibiotic development by promoting greater collaboration within the entire antibiotic development community, and by tackling key challenges to the development of new medicines.

More... »

Critical Pharma completes second trial on CP024 intranasal growth hormone

Wednesday, February 13, 2013 12:13 PM

Critical Pharmaceuticals, a Nottingham, U.K.-based biotechnology company, has successfully completed a second clinical study on its CP024 growth hormone nasal spray.

More... »

e-Therapeutics to raise $62 million for cancer drug, network pharmacology platform

Monday, February 11, 2013 02:08 PM

Drug discovery and development company e-Therapeutics has proposed raising $62 million through an issue of new ordinary shares to existing and new institutional investors.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »